Cardiac Rhythm News

Sep 30, 2021 | Cardiac Rhythm News
Abbott’s Amplatzer Talisman gains FDA approval

Abbott has announced that the US Food and Drug Administration (FDA) has approved the company’s Amplatzer Talisman PFO Occlusion System to treat people with a patent foramen ovale (PFO)—a small opening between the upper chambers of the heart—who are at risk of recurrent ischaemic stroke.

Aug 2, 2021 | Cardiac Rhythm News
Tyrx envelope shown to be cost effective in European healthcare markets

Economic analyses from the WRAP-IT study, sponsored by Medtronic, demonstrate the Tyrx cardiac absorbable antibacterial envelope’s (Tyrx Envelope) cost effectiveness in European markets for patients at increased risk of infections.

Jun 23, 2021 | Cardiac Rhythm News
Expanded FDA approval for Medtronic’s Arctic Front cryoablation catheter

Medtronic has received US Food and Drug Administration (FDA) expanded approval for the Arctic Front family of cardiac cryoablation catheters for the treatment of recurrent symptomatic paroxysmal atrial fibrillation (AF) as an alternative to antiarrhythmic drug (AAD) therapy as an initial rhythm control strategy.

May 25, 2021 | Cardiac Rhythm News
iRhythm gains two FDA approvals for updates to its Zio system

iRhythm Technologies has announced two US Food and Drug Administration (FDA) 510K clearances—one for a new and improved design of its flagship monitor and a second for updated artificial intelligence (AI) capabilities.

May 12, 2021 | Cardiac Rhythm News
Cardiology trainees require training to adapt to shift towards telemedicine

A significant proportion of cardiology trainees are uncomfortable with using telemedicine and feel that better preparation for new-tech medicine is needed, findings of a survey published in the Canadian Journal of Cardiology indicate.

May 6, 2021 | Cardiac Rhythm News
Abbott initiates trial focusing on twin AF and heart failure treatments

Abbott has announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AF) and heart failure.

Apr 30, 2021 | Cardiac Rhythm News
EHRA 2021: Subcutaneous ICDs maintain cardioversion efficacy of 98% across five-year study

Subcutaneous implantable cardioverter-defibrillator (S-ICD) devices have demonstrated a cardioversion efficacy rate of 98% over a period of at least five years in the EFFORTLESS study—the results of which were presented in a late-breaking presentation at the 2021 European Heart Rhythm Association congress.

Apr 14, 2021 | Cardiac Rhythm News
MultiPulse therapy “shows promise” in the treatment of AF

Cardialen has announced the publication of a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology investigating its low-voltage MultiPulse therapy to terminate atrial fibrillation (AF).

Jan 13, 2021 | Cardiac Rhythm News
Regular alcohol consumption linked to increased AF risk

A study of nearly 108,000 people has found that people who regularly drink a modest amount of alcohol are at increased risk of atrial fibrillation (AF).

Dec 16, 2020 | Cardiac Rhythm News
CardioFocus announces 10,000-patient milestone for HeartLight ablation system

The HeartLight System is a catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for atrial fibrillation (AF). HeartLight is a treatment option for some patients whose AF is insufficiently controlled with medication.

Filter by Journal